CA
NZ
UK
AU
IND
US
…
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Candel Therapeutics is a clinical-stage biotechnology company developing oncolytic viral immunotherapies for solid tumors; public disclosures about specific programmes and timelines are limited. Long-term growth drivers may include positive clinical data, regulatory progress, and partnerships that could support adoption and scale-up. The company may appeal to investors seeking exposure to novel cancer immunotherapy approaches if efficacy and safety are demonstrated.
Primary investment risks include clinical and regulatory failure, ongoing cash burn and financing needs, manufacturing scale-up complexity, and intense competition in oncology.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M |
| Net income | -38.18M | -55.18M | -37.94M | -2.87M | -36.12M |
| Selling general administrative | 17.77M | 14.06M | 13.72M | 14.06M | 10.67M |
| Selling and marketing expenses | - | - | 0.69M | - | - |
| Gross profit | -0.84M | -0.99M | -23.98M | 0.12M | 0.12M |
| Reconciled depreciation | 0.84M | 0.99M | 0.93M | 0.78M | 0.23M |
| Ebit | -48.27M | -53.09M | -38.39M | -34.72M | -36.07M |
| Ebitda | -47.42M | -52.10M | -37.43M | -51.04M | -35.84M |
| Depreciation and amortization | 0.84M | 0.99M | 0.96M | -16.32M | 0.23M |
| Non operating income net other | - | - | - | - | -10.40M |
| Operating income | -48.27M | -33.37M | -38.39M | -34.72M | -25.73M |
| Other operating expenses | 48.27M | 33.37M | 38.39M | 34.80M | 24.77M |
| Interest expense | 2.12M | 2.09M | 0.51M | 0.49M | 0.05M |
| Interest income | 3.92M | 1.09M | 2.08M | - | - |
| Net interest income | 1.80M | -1.00M | -0.03M | -0.49M | -0.05M |
| Income tax expense | - | - | - | -15.93M | 10.40M |
| Total revenue | 0.00M | 0.00M | 0.03M | 0.12M | 0.12M |
| Total operating expenses | 47.42M | 32.38M | 14.41M | 34.80M | 25.85M |
| Cost of revenue | 0.84M | 0.99M | 23.98M | - | - |
| Total other income expense net | 10.08M | -21.81M | 0.45M | 15.93M | -10.40M |
| Net income from continuing ops | -38.18M | -55.18M | -31.93M | -18.79M | -36.12M |
| Net income applicable to common shares | - | - | - | -18.79M | -36.12M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 125.19M | 106.87M | 41.70M | 77.69M | 89.20M |
| Other current assets | 1.66M | 1.15M | 1.38M | 1.89M | 2.30M |
| Total liab | 73.27M | 40.54M | 28.96M | 29.98M | 25.07M |
| Total stockholder equity | 51.92M | 66.33M | 12.74M | -99.09M | 64.14M |
| Deferred long term liab | - | - | - | - | 0.89M |
| Other current liab | 7.42M | 26.83M | 4.36M | 4.63M | 3.77M |
| Common stock | 0.55M | 0.47M | 0.29M | 0.29M | 0.29M |
| Capital stock | 0.55M | 0.47M | 0.29M | 0.29M | 0.29M |
| Retained earnings | -230.39M | -192.21M | -137.03M | -99.09M | -80.30M |
| Other liab | - | - | - | 2.03M | 19.15M |
| Other assets | - | - | - | 0.27M | 0.42M |
| Cash | 119.73M | 102.65M | 35.41M | 70.06M | 82.64M |
| Total current liabilities | 9.00M | 37.53M | 14.18M | 5.62M | 5.36M |
| Current deferred revenue | - | - | - | 0.14M | - |
| Net debt | -117.83M | -89.18M | -12.65M | -47.26M | -82.08M |
| Short term debt | 0.45M | 10.46M | 9.41M | 0.46M | - |
| Short long term debt | - | 9.89M | 8.89M | - | - |
| Short long term debt total | 1.90M | 13.47M | 22.76M | 22.80M | 0.56M |
| Other stockholder equity | 281.76M | 258.06M | 149.48M | -0.29M | 144.15M |
| Property plant equipment | - | - | - | 5.48M | 3.84M |
| Total current assets | 119.73M | 103.80M | 36.80M | 71.94M | 84.94M |
| Net tangible assets | - | - | - | 47.71M | 64.14M |
| Long term debt | 47.13M | 2.60M | 12.38M | 20.85M | 0.56M |
| Accounts payable | 1.13M | 0.24M | 0.42M | 0.38M | 1.59M |
| Accumulated other comprehensive income | - | 0.00M | 0.00M | - | -89.20M |
| Common stock total equity | - | - | - | - | 0.29M |
| Retained earnings total equity | - | - | - | - | -80.30M |
| Non currrent assets other | 5.05M | 0.33M | 0.12M | 0.27M | 0.42M |
| Non current assets total | 5.46M | 3.06M | 4.91M | 5.75M | 4.26M |
| Capital lease obligations | 1.90M | 0.97M | 1.49M | 1.95M | - |
| Long term debt total | - | - | - | - | 0.56M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.02M | -0.53M | -1.30M | -1.83M |
| Change to liabilities | - | - | - | -1.15M | 0.97M |
| Total cashflows from investing activities | -0.56M | -0.02M | -0.28M | -1.30M | -1.83M |
| Net borrowings | 36.21M | -9.17M | 0.00M | 19.91M | 19.91M |
| Total cash from financing activities | 56.10M | 94.28M | -0.12M | 19.97M | 71.80M |
| Change to operating activities | - | - | - | 1.22M | -1.42M |
| Net income | -38.18M | -55.18M | -37.94M | -18.79M | -36.12M |
| Change in cash | 17.23M | 67.24M | -34.65M | -12.74M | 47.75M |
| Begin period cash flow | 102.92M | 35.68M | 70.32M | 83.07M | 35.32M |
| End period cash flow | 120.15M | 102.92M | 35.68M | 70.32M | 83.07M |
| Total cash from operating activities | -38.31M | -27.02M | -34.24M | -31.42M | -22.22M |
| Issuance of capital stock | 19.37M | 101.76M | 0.00M | 0.00M | 71.33M |
| Depreciation | 0.84M | 0.99M | 1.28M | 0.78M | 0.23M |
| Other cashflows from investing activities | 0.03M | - | 0.18M | - | - |
| Sale purchase of stock | - | - | -0.12M | - | 71.80M |
| Other cashflows from financing activities | 56.10M | 1.69M | -0.12M | 19.97M | 0.47M |
| Change to netincome | - | - | - | -13.77M | 14.46M |
| Capital expenditures | 0.59M | 0.02M | 0.46M | 1.30M | 1.83M |
| Cash flows other operating | - | - | - | - | -1.75M |
| Cash and cash equivalents changes | - | - | - | - | 47.75M |
| Change in working capital | 2.19M | 0.35M | -0.38M | 0.07M | -0.88M |
| Stock based compensation | 3.82M | 5.31M | 3.09M | 2.31M | 2.96M |
| Other non cash items | -6.98M | 21.51M | -0.30M | -15.78M | 0.08M |
| Free cash flow | -38.90M | -27.04M | -34.70M | -32.72M | -24.05M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CADL Candel Therapeutics Inc |
0.25 3.08% |
8.37 | - | 43.48 | 436.42 | 10.19 | 821.98 | -0.01 |
| NVO Novo Nordisk A/S |
-0.04 0.09% |
40.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-12.16 2.20% |
540.99 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
9.56 0.99% |
970.83 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. | Pres, CEO & Director | 1960 |
| Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. | Founder & Director | 1958 |
| Ms. Carrie Smith Cox | Special Advisor to the CEO | 1958 |
| Mr. Jason A. Amello | Chief Financial Officer | 1968 |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Devel. Officer | 1967 |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 1978 |
| Ms. Ileen B. Winick | Chief People Officer | NA |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | 1961 |
| Mr. Nathan Caffo | Chief Bus. Officer | 1969 |
| Dr. William Garrett Nichols M.D., M.S., MS | Chief Medical Officer | 1969 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-0.17%
Communication Services
+0.18%
Consumer Cyclical
+0.51%
Consumer Defensive
+0.42%
Energy
-1.23%
Financial Services
+0.48%
Financials
+0.41%
Healthcare
+0.23%
Industrials
+0.31%
Real Estate
+0.26%
Technology
+0.11%
Utilities
+0.05%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...